$6.01
0.17% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Enanta Pharmaceuticals, Inc. Stock price

$6.01
-2.82 31.94% 1M
-6.66 52.57% 6M
-3.40 36.13% YTD
-3.64 37.72% 1Y
-69.56 92.05% 3Y
-56.50 90.39% 5Y
-45.97 88.44% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
+0.01 0.17%
ISIN
US29251M1062
Symbol
ENTA
Sector
Industry

Key metrics

Market capitalization $127.38m
Enterprise Value $104.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.55
P/S ratio (TTM) P/S ratio 1.88
P/B ratio (TTM) P/B ratio 0.99
Revenue growth (TTM) Revenue growth -14.61%
Revenue (TTM) Revenue $67.64m
EBIT (operating result TTM) EBIT $-121.69m
Free Cash Flow (TTM) Free Cash Flow $-96.71m
Cash position $248.79m
EPS (TTM) EPS $-5.49
P/E forward negative
P/S forward 1.78
EV/Sales forward 1.46
Short interest 17.26%
Show more

Is Enanta Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Enanta Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

4x Buy
50%
3x Hold
38%
1x Sell
13%

Analyst Opinions

8 Analysts have issued a Enanta Pharmaceuticals, Inc. forecast:

Buy
50%
Hold
38%
Sell
13%

Financial data from Enanta Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
68 68
15% 15%
100%
- Direct Costs 2.34 2.34
1% 1%
3%
65 65
15% 15%
97%
- Selling and Administrative Expenses 53 53
10% 10%
79%
- Research and Development Expense 131 131
20% 20%
194%
-119 -119
11% 11%
-176%
- Depreciation and Amortization 2.34 2.34
1% 1%
3%
EBIT (Operating Income) EBIT -122 -122
11% 11%
-180%
Net Profit -116 -116
13% 13%
-172%

In millions USD.

Don't miss a Thing! We will send you all news about Enanta Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Enanta Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
5 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced that the United States District Court of Massachusetts (“the Court”) has issued a ruling on a summary judgment motion filed by Pfizer, Inc. in connection with Enanta's patent inf...
Neutral
Business Wire
20 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from the first-in-pediatrics Phase 2 study evaluating zelicapavir in hospitalized and non-hospitalized children aged 28 days to 36 months with respiratory...
Neutral
Business Wire
22 days ago
WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the company will hold a conference call and webcast on Monday, December 9 at 8:30 a.m. ET to share topline results from RSVPEDs, a first-in-pediatrics Phase 2 study evaluating zel...
More Enanta Pharmaceuticals, Inc. News

Company Profile

Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Head office United States
CEO Jay Luly
Employees 131
Founded 1995
Website www.enanta.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today